In a large prospective study with 239 patients, Dam et al. showed only a weak association between change in plasma CgA and change in tumor burden in a cohort of GEP‐NET patients, suggesting that CgA as a single biomarker is inadequate to predict tumor progression.10 This evidence concerns the gene CGA and neoplasm.